Rachel Cole
Psychiatric/Mental Health · Hopkinsville, KYNPI 1104348358
Payments from drug & device makers
Across 1,290 payments — averaging $390.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$476K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$21K
- Johnson & Johnson$1K
- Alkermes, Inc.$490
- Teva Pharmaceuticals USA, Inc.$473
- Ironshore Pharmaceuticals Inc.$471
- plus $3K from 13 others
What the payments were for
- Consulting fees$3,7201%
- Speaking & faculty fees$444,70588%
- Travel & lodging$38,9048%
- Food & beverage$15,5793%
- Education$1870%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 859 | $476,353 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $21,382 |
| Johnson & Johnson(2 entities) | 92 | $1,244 |
| Alkermes, Inc. | 30 | $490 |
| Teva Pharmaceuticals USA, Inc. | 33 | $473 |
| Ironshore Pharmaceuticals Inc. | 52 | $471 |
| E.r. Squibb & Sons, L.L.C. | 25 | $455 |
| Otsuka America Pharmaceutical, Inc. | 19 | $418 |
| Lundbeck LLC | 19 | $334 |
| Vanda Pharmaceuticals Inc. | 15 | $330 |
| Neurocrine Biosciences, Inc. | 22 | $329 |
| Sunovion Pharmaceuticals Inc. | 17 | $221 |
| Corium, LLC | 7 | $178 |
| Axsome Therapeutics, Inc. | 9 | $132 |
| Supernus Pharmaceuticals, Inc. | 7 | $130 |
| Takeda Pharmaceuticals U.S.A., Inc. | 4 | $70 |
| Collegium Pharmaceutical, Inc. | 3 | $47 |
| Almatica Pharma LLC | 1 | $21 |
| Indivior Inc. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$503,095 in reported general payments places this provider in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VraylarCariprazine Hcl | 226 | $329,285 |
| CaplytaLumateperone Tosylate | 71 | $120,688 |
| IngrezzaValbenazine Tosylate | 14 | $111,510 |
| Abilify MaintenaAripiprazole | 37 | $103,554 |
| Invega SustennaPaliperidone Palmitate | 35 | $102,201 |
| RexultiBrexpiprazole | 24 | $34,811 |
| TrintellixVortioxetine Hydrobromide | 41 | $19,787 |
| Lurasidone Hcl | 44 | $19,633 |
| VyvanseLisdexamfetamine Dimesylate | 33 | $12,415 |
| Quetiapine Fumarate ErQuetiapine Fumarate | 63 | $7,683 |
| Aripiprazole | 127 | $7,053 |
| Paliperidone ErPaliperidone | 20 | $6,000 |
| Lisdexamfetamine Dimesylate | 31 | $5,948 |
| Desvenlafaxine Succinate ErDesvenlafaxine Succinate | 74 | $5,114 |
| Quetiapine Fumarate | 275 | $4,132 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar | $476,353 | $329,285226 claims |
| Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti | $418 | $138,36461 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $21,382 | $120,68871 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $329 | $111,51014 claims |
| Johnson & JohnsonInvega Sustenna | $1,244 | $102,20135 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix, Vyvanse | $70 | $32,20274 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 946 psychiatric/mental health providers in Kentucky.
Other psychiatric/mental health in Hopkinsville
- Hope SmithHopkinsville$68K
- Brett BondHopkinsville$7K
- Theresa WattsAshland$645K
- Denise de AngelisLouisville$384K
- Jennifer SampangCrestview Hills$322K
- Jeremy FisherSouth Shore$197K
- Jessica EstesLewisport$175K
- Christopher MulloneyNancy$95K
- Davika MattoxMorehead$79K
- Molly LutzCrestview Hills$71K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.